STOCK TITAN
  1. Home
  2. News
  3. BHC

Bausch Health Companies Inc. - BHC STOCK NEWS

Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.

With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.

Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.

Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.

Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.

For more information, visit www.bauschhealth.com.

News

Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22

Rhea-AI Summary
Bausch Health Companies Inc. (BHC) will release its Q4 and full-year 2023 financial results on Feb. 22, 2024. A conference call and webcast will follow to discuss the results and provide a business update. The materials will be available on the Investor Relations section of the Bausch Health website. The live Q&A session will require registration to receive a PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
earnings
-
News

CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.

Rhea-AI Summary
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, have announced the U.S. launch of CABTREO, a topical gel for the treatment of acne vulgaris. The gel is the first FDA-approved fixed-dose, once-daily triple-combination topical treatment for acne, offering three mechanisms of action. It has shown statistically significant reductions in both inflammatory and non-inflammatory lesions compared to a vehicle gel, with 50.0% of participants achieving treatment success with CABTREO versus 22.6% with the vehicle gel at week 12. However, the gel has also shown some common adverse reactions, including application site reactions, pain, erythema, dryness, irritation, exfoliation, and dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Rhea-AI Summary
Bausch Health Companies Inc. and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China's National Medical Products Administration. This is a significant milestone for Solta Medical and represents a major breakthrough in one of the largest medical aesthetics markets. The approval allows the companies to continue the growth of Thermage in China, a non-invasive treatment that uses radiofrequency technology to tighten and improve the skin's surface. The approval is expected to drive business growth and expand the reach of Thermage FLX proven technology to the Chinese market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
News

Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Rhea-AI Summary
Bausch Health Companies Inc. and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China's NMPA. The approval is significant for Solta Medical and represents an important breakthrough in the medical aesthetics market. The approval allows the companies to continue the momentum of the growth of Thermage in China, which has been serving Chinese institutions and consumers effectively since 2015. Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface. It is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body, and around the eyes. Globally, more than two million Thermage treatments have been performed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News

Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and Salix Pharmaceuticals, a subsidiary, announced oral arguments at the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued, and the company looks forward to the Court's decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
News

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced positive topline results from the Phase 2 study of Amiselimod for the treatment of ulcerative colitis. The study met both primary and key secondary endpoints, with impressive efficacy results and a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
clinical trial
News

DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan

Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced that DUOBRII, a novel topical prescription drug for plaque psoriasis, is now available to patients enrolled in Quebec's public drug plan. The drug is already available on most other public drug plans in Canada and the NIHB program. Manufactured in Quebec, it has been available by prescription since August 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
News

Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

Rhea-AI Summary
Salix Pharmaceuticals (BHC) partners with USPF and IFFGD to declare Opioid-Induced Constipation (OIC) Awareness Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
none
-
News

KBRA Releases Third-Quarter 2023 U.S. Bank Compendium and 2024 Outlook

Rhea-AI Summary
KBRA releases its third-quarter 2023 U.S. Bank Compendium and 2024 Outlook, providing the latest view of the U.S. banking industry. The report discusses earnings generation, NIM stabilization, funding costs, credit trends, and core capital measures. It also includes a regulatory recap and features WSFS Financial Corporation. The Compendium provides 3Q23 summaries on all publicly traded U.S. banks in KBRA’s rated universe, along with key performance and credit metrics. It also includes the top 10 lowest cost deposit franchises, highest reserves to loans, and largest sequential changes in financial ratios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
News

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Rhea-AI Summary
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and Salix Pharmaceuticals announced findings from a hospital database analysis showing that the lack of a specific diagnostic code for OHE may lead to increased hospitalization costs and length of stay. The analysis revealed that using in-hospital rifaximin or lactulose in combination with certain diagnosis codes resulted in 2.5 times higher hospital billing charges and a 2.0 times longer length of stay compared to relying solely on OHE as a primary diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

The current stock price of Bausch Health Companies (BHC) is $8.48 as of November 15, 2024.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately 3.2B.

What are the primary areas of focus for Bausch Health?

Bausch Health specializes in eye health, gastroenterology, and dermatology.

How many employees does Bausch Health have?

Bausch Health employs approximately 22,000 people worldwide.

In how many countries does Bausch Health operate?

Bausch Health operates in around 100 countries.

What is Bausch Health's largest revenue-generating segment?

The Bausch + Lomb segment generates the highest revenue for Bausch Health.

What recent product development has Bausch Health achieved?

Bausch Health has made significant progress with Amiselimod, a new treatment for ulcerative colitis.

What financial performance did Bausch Health report for Q1 2024?

Bausch Health reported Q1 2024 revenues of $2.15 billion, an 11% increase from the previous year.

How is Bausch Health protecting its intellectual property?

Bausch Health is actively involved in litigation to defend its intellectual property, particularly for the XIFAXAN® franchise.

Where can I find more information about Bausch Health?

More information is available at www.bauschhealth.com.

What recent public drug plan listings has Bausch Health achieved in Canada?

UCERIS® aerosol foam has been listed in the public drug plans of several Canadian provinces, including Ontario, Quebec, and Alberta.

Who is the brand ambassador for the XIFAXAN® awareness campaign?

Award-winning actor Bellamy Young is the brand ambassador for the XIFAXAN® awareness campaign.

Stock BHC logo
Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

#1623 Ranked by Market Cap
N/A Ranked by Dividends

BHC Stock Data

3.17B
367.80M
11.08%
77.48%
3.27%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
QUEBEC